ES2160595T3 - Tratamiento de hepatomas con analogos de somatostatina. - Google Patents

Tratamiento de hepatomas con analogos de somatostatina.

Info

Publication number
ES2160595T3
ES2160595T3 ES93907029T ES93907029T ES2160595T3 ES 2160595 T3 ES2160595 T3 ES 2160595T3 ES 93907029 T ES93907029 T ES 93907029T ES 93907029 T ES93907029 T ES 93907029T ES 2160595 T3 ES2160595 T3 ES 2160595T3
Authority
ES
Spain
Prior art keywords
phe
somatostatine
hepatomas
analogs
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93907029T
Other languages
English (en)
Inventor
Arthur E Bogden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Bioscience Inc
Original Assignee
Ipsen Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Bioscience Inc filed Critical Ipsen Bioscience Inc
Application granted granted Critical
Publication of ES2160595T3 publication Critical patent/ES2160595T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/31Somatostatins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/655Somatostatins
    • C07K14/6555Somatostatins at least 1 amino acid in D-form

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

UN METODO DE TRATAMIENTO DE CANCER DE HIGADO EN UN SUJETO MAMIFERO. EL METODO COMPRENDE LA ADMINISTRACION AL SUJETO DE UNA COMPOSICION QUE CONTIENE UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE UN OCTAPEPTIDO DE LA SIGUIENTE FORMULA: H-A1-CYS-AGAMMA-D-TRP-LYS-A3-CYS-A4-Y, EN LA QUE A1 ES D-BETA-NAL O D-PHE; A2 ES PHE, PENTAFLUOR-PHE O X-PHE P-SUSTITUIDO CONDE X ES UN HALOGENO; NH2, NO2, OH O C1-3ALKILO; A3 ES THR, SER, PHE, VAL, ACIDO ALFA-AMINOBUTIRICO O ILE; A4 ES THR, BETA-NAL O TRP; EY ES NH2 O OH; O UN SAL FARMACEUTICAMENTE ACEPTABLE O UN COMPLEJO DE ESTA.
ES93907029T 1992-02-25 1993-02-25 Tratamiento de hepatomas con analogos de somatostatina. Expired - Lifetime ES2160595T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/840,881 US5411943A (en) 1992-02-25 1992-02-25 Hepatoma treatment with somatostatin analogs

Publications (1)

Publication Number Publication Date
ES2160595T3 true ES2160595T3 (es) 2001-11-16

Family

ID=25283467

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93907029T Expired - Lifetime ES2160595T3 (es) 1992-02-25 1993-02-25 Tratamiento de hepatomas con analogos de somatostatina.

Country Status (9)

Country Link
US (1) US5411943A (es)
EP (1) EP0585444B1 (es)
JP (1) JPH06507423A (es)
AT (1) ATE203410T1 (es)
CA (1) CA2107773A1 (es)
DE (1) DE69330483T2 (es)
DK (1) DK0585444T3 (es)
ES (1) ES2160595T3 (es)
WO (1) WO1993016718A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760000A (en) * 1994-05-13 1998-06-02 University Technologies International,Inc. Inhibition of liver cancer by the use of GnRH and GnRH analogs
US5830431A (en) * 1995-06-07 1998-11-03 Mallinckrodt Medical, Inc. Radiolabeled peptide compositions for site-specific targeting
US6080728A (en) * 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
US6355613B1 (en) * 1996-07-31 2002-03-12 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
US6150333A (en) * 1998-07-30 2000-11-21 Biomeasure, Inc. Methods of using a somatostatin analogue
US6465613B1 (en) 1998-11-19 2002-10-15 Tulane University Hydrophilic somatostatin analogs
CN1589151A (zh) 2001-09-21 2005-03-02 图兰恩教育基金管理人 诊断或治疗性促生长素抑制素或铃蟾肽类似物的连接物及其用途
US7771727B2 (en) * 2002-03-01 2010-08-10 The Administrators Of The Tulane Educational Fund Conjugates of therapeutic or cytotoxic agents and biologically active peptides
CA2518406A1 (en) * 2003-03-10 2004-09-23 Biogen Idec Ma Inc. Thiol-mediated drug attachment to targeting peptides
EP2190453A2 (en) * 2007-09-11 2010-06-02 Mondobiotech Laboratories AG Use of trp6-triptorelin and d-leu6-leuprolide as therapeutic agents
WO2009033739A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073541A (en) * 1987-11-18 1991-12-17 Administrators Of The Tulane Educational Fund Treatment of small cell lung cancer with somatostatin analogs
WO1991009056A1 (en) * 1989-12-08 1991-06-27 The Administrators Of The Tulane Educational Fund Octapeptide analogs of somatostatin having threonine at the sixth position

Also Published As

Publication number Publication date
HK1015123A1 (en) 1999-10-08
ATE203410T1 (de) 2001-08-15
EP0585444B1 (en) 2001-07-25
EP0585444A4 (en) 1996-01-10
DE69330483D1 (de) 2001-08-30
JPH06507423A (ja) 1994-08-25
CA2107773A1 (en) 1993-08-26
WO1993016718A1 (en) 1993-09-02
DK0585444T3 (da) 2001-09-24
DE69330483T2 (de) 2002-06-13
EP0585444A1 (en) 1994-03-09
US5411943A (en) 1995-05-02

Similar Documents

Publication Publication Date Title
ES2160595T3 (es) Tratamiento de hepatomas con analogos de somatostatina.
PT871440E (pt) Tratamento de sintomas negativos e cognitivos de esquizofrenia com antagonistas da captacao de glicina
IT1252868B (it) Composizione farmaceutica anticefalalgica per somministrazione endonasale, procedimento per prepararla e suo impiego terapeutico
ATE71947T1 (de) Tetrapyrrol-therapiemittel.
EP0938317A4 (en) COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION
KR900003205A (ko) 제약 화합물
EP1077721A4 (en) VENTILATION AND TREATMENT OF HYPERGASTRINEMY
ES2106531T3 (es) Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso.
ES482415A1 (es) Procedimiento para la preparacion de la sal de 4-aminohex-5-inoico o una sal del mismo.
ES461987A3 (es) Procedimiento para la fabricacion de nuevos gona-4,9 (10) dienos.
DE3167826D1 (en) Peptides and their therapeutic use
IL137820A0 (en) Pharmaceutical composition comprising an analgesic peptide
KR910000794A (ko) Vip-유사체 ⅱ
IL93989A0 (en) Pharmaceutical compositions comprising heteroaryl-3-oxo-propanenitrile derivatives useful in the treatment of rheumatoid arthritis and other autoimmune diseases
ES8103071A1 (es) Procedimiento de preparacion de nuevos derivados aminicos del benzotiazol
ATE546461T1 (de) Gnrh analog von nicht-säugertieren und verwendung zur regulierung der fruchtbarkeit und der schwangerschaft
NZ337601A (en) Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics by inhibiting IgE expression
ES8701784A1 (es) Un procedimiento para preparar un peptido ciclico con acti- vidad antagonista de vasopresina
DE69220050D1 (de) Verfahren zur inhibierung der fibrose
US4395400A (en) Nonapeptide, a process for its preparation, an agent containing it and its use
KR880013902A (ko) 아미노산 유도체
EP0248231A3 (en) Pharmacologically active peptides
DE3365954D1 (en) The use of alpha, alpha-dialkyl adamanthylethylamines to treat measles
SE8006333L (sv) Polypeptid psp och salter derav
DE69312322D1 (de) Cephem verbindungen mit antimicrobizide eigenschaften

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 585444

Country of ref document: ES